Scarica l'app Stockscreener
270.45
1.81%
-4.98
Precedente Chiudi:
$275.43
Aprire:
$275.43
Volume 24 ore:
375.37K
Relative Volume:
0.49
Capitalizzazione di mercato:
$17.74B
Reddito:
$1.01B
Utile/perdita netta:
$581.90M
Rapporto P/E:
30.48
EPS:
8.8733
Flusso di cassa netto:
$50.57M
1 W Prestazione:
-1.48%
1M Prestazione:
+28.91%
6M Prestazione:
+33.23%
1 anno Prestazione:
+53.24%
Intervallo 1D:
$267.85
$276.91
Intervallo di 1 settimana:
$265.37
$282.15
Portata 52W:
$160.86
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Nome
Ascendis Pharma A S
Settore
Industria
Telefono
-
Indirizzo
-
Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
270.45 | 17.74B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-17 | Iniziato | Raymond James | Strong Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-05-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Iniziato | Stifel | Buy |
| 2023-12-20 | Iniziato | Jefferies | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Neutral |
| 2023-04-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-08-30 | Ripresa | Berenberg | Buy |
| 2022-03-28 | Ripresa | Wedbush | Outperform |
| 2022-03-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Iniziato | Cowen | Market Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-30 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Ripresa | Stifel | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-03-20 | Iniziato | Oppenheimer | Outperform |
| 2019-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2019-03-25 | Iniziato | Evercore ISI | Outperform |
| 2019-01-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Iniziato | Stifel | Buy |
| 2018-04-02 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-05-11 | Iniziato | JP Morgan | Overweight |
| 2017-03-09 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Iniziato | Credit Suisse | Outperform |
| 2016-09-26 | Iniziato | Wedbush | Outperform |
Mostra tutto
Ascendis Pharma A S Borsa (ASND) Ultime notizie
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Yahoo Finance
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong - simplywall.st
Price to earnings forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to revenue forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Ascendis Pharma (ASND) Investor Update Summary - Quartr
Ascendis Pharma (ASND) Q3 2025 earnings summary - Quartr
Ascendis Pharma (ASND) Q3 2024 earnings summary - Quartr
Ascendis Pharma (ASND) Q2 2024 earnings summary - Quartr
RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $280 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Ascendis Pharma Q2 2025 Earnings Preview - MSN
Ascendis Pharma: Behind The Stock Surge - Seeking Alpha
Ascendis Pharma : ASND - 24/7 Wall St.
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexes - MSN
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia - TipRanks
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia - marketscreener.com
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TipRanks
Ascendis Pharma A/SAnnounces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia - TradingView
Ascendis drug data show leg alignment kept improving through 2 years - Stock Titan
Children with Achondroplasia Treated with TransCon CNP - GlobeNewswire
Big Pharma Has a Case of Merger Mania - The Motley Fool
Ascendis Pharma A/S(NasdaqGS:ASND) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital - TipRanks
Ascendis Pharma (ASND) adds 177,267 shares via warrant exercises - Stock Titan
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 2500 Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Value Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Growth Benchmark - marketscreener.com
Sit Mid Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $288 - 富途牛牛
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Value Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Index - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Index - marketscreener.com
Ascendis Pharma (ASND) moves 9.9% higher: Will this strength last? - MSN
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Index - marketscreener.com
Ascendis Pharma added to Russell 1000 and other indexes By Investing.com - Investing.com Australia
Ascendis Pharma joins multiple Russell U.S. indexes, boosting its market visibility. - Pluang
Ascendis Pharma added to Russell 1000 and other indexes - Investing.com UK
Ascendis Pharma A/S Actuals & Estimates (NASDAQ:ASND) - TradingView
Ascendis Pharma (ASND) Joins Russell Indexes in 2026 Reconstitution - GuruFocus
Ascendis Pharma (ASND) Joins Multiple Russell Indexes - GuruFocus
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap - marketscreener.com
Ascendis Joins Multiple Russell U.S. Indexes, Including the - GlobeNewswire
Ascendis Pharma A S Azioni (ASND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ascendis Pharma A S Azioni (ASND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):